 |
市場調查報告書
商品編碼
1441342
全球癌症生物標記市場規模、佔有率、成長分析（依分析技術、生物分子、癌症、應用）- 2023-2030 年產業預測Global Cancer Biomarkers Market Size, Share, Growth Analysis, By Profiling Technology, By Biomolecules, By Cancer, By Application - Industry Forecast 2023-2030 |
||||||
2022年全球癌症生物標記市場規模為132.4億美元，預計將從2023年的148.3億美元成長到2031年的294.9億美元，預測期內（2024-2031年）複合CAGR為13.6%
全球癌症生物標記市場的預期擴張顯示多種癌症的發生率顯著增加，包括肺癌、前列腺癌和乳腺癌。癌症病例的增加將推動預測期內市場的成長。
此外，標靶和生物療法在癌症治療中日益重要，也推動了對有效生物標記的需求。這種上升趨勢得到了技術進步的進一步支持，這些技術進步提高了癌症生物標記的精確度和一致性，從而提高了治療監測和診斷能力。
全球癌症生物標記市場區隔分析
全球癌症生物標記市場由五個部分組成：分析技術、癌症類型、生物分子、應用和地理。根據分析技術，市場分為四個部分：基於細胞遺傳學的測試、免疫分析、影像技術和組學技術。市場根據生物分子分為四個部分：遺傳、蛋白質、糖和表觀遺傳生物標記。市場依癌症種類分為：乳癌、肺癌、大腸癌、攝護腺癌、胃癌等。該市場根據應用分為五個部分：風險評估、預測、藥物發現和開發、診斷等。市場分為以下區域：亞太地區、日本、中國、印度、韓國、澳洲、亞太地區其他地區、拉丁美洲、巴西、沙烏地阿拉伯、歐洲其他地區、北美、美國、加拿大、墨西哥、歐洲、德國、英國、義大利、法國、西班牙和拉丁美洲地區其他地區。
全球生物樣本庫市場的促進因素
許多製藥公司正在大力投資尖端研究和開發項目，這些項目以專為癌症檢測和治療而設計的新生物標記為中心。許多令人感興趣的潛在客戶的發展階段已接近尾聲，在首次亮相時應該會取得顯著進步。這些可能的生物標記有能力透過提高精確度和有效性來徹底改變癌症的診斷和治療方式。
全球癌症生物標記市場的限制
癌症生物標記產業的一個主要障礙與全球癌症盛行率不斷上升以及對診斷工具不斷成長的需求形成鮮明對比。成熟國家和新興國家都缺乏全面的生物標記測試報銷規則。這項缺陷阻礙了這些基本診斷工具的廣泛採用，從而限制了全球對生物標記的需求。另一個重大障礙是癌症檢測和治療的高昂費用，這在發展中國家尤其常見。
全球癌症生物標記市場趨勢
由於許多重要因素的結合，癌症生物標記市場預計在未來十年將顯著成長。患者和醫療保健專業人士對惡性腫瘤治療早期檢測需求的認知不斷增強是這一成長的關鍵因素。這種意識的提高鼓勵以積極主動的方式進行早期診斷，從而及時進行治療，從而可能帶來更好的治療結果。
目錄
執行摘要
- 市場概況
- 命運之輪
研究方法論
- 資訊採購
- 二手和主要資料來源
- 市場規模估計
- 市場假設與限制
母公司市場分析
- 市場概況
- 市場規模
- 市場動態
- 促進要素
- 機會
- 限制
- 課題
主要市場洞察
- 技術分析
- 定價分析
- 供應鏈分析
- 價值鏈分析
- 市場生態系統
- 智慧財產權分析
- 貿易分析
- 啟動分析
- 原料分析
- 創新矩陣
- 管道產品分析
- 總體經濟指標
- 頂級投資分析
- 成功的關鍵因素
- 競爭程度
市場動態與展望
- 市場動態
- 促進要素
- 機會
- 限制
- 課題
- 監管環境
- 波特分析
- 對未來顛覆的特別見解
依分析技術分類的全球癌症生物標記市場
- 市場概況
- 歐米克科技
- 影像技術
- 免疫測定
- 基於細胞遺傳學的測試
依生物分子分類的全球癌症生物標記市場
- 市場概況
- 基因生物標記
- 蛋白質生物標記
- 表觀遺傳學
- 和糖生物標記
依癌症分類的全球癌症生物標記市場
- 市場概況
- 乳癌
- 肺癌
- 大腸直腸癌
- 攝護腺癌
- 胃癌
- 和別的
全球癌症生物標記市場（依應用）
- 市場概況
- 診斷
- 藥物發現與開發
- 預測
- 風險評估
- 和別的
依地區分類的全球癌症生物標記市場規模
- 市場概況
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 西班牙
- 法國
- 英國
- 歐洲其他地區
- 亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
- 拉丁美洲
- 巴西
- 拉丁美洲其他地區
- 中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- MEA 的其餘部分
競爭格局
- 前 5 名企業比較
- 2021 年關鍵參與者的市場定位
- 主要市場參與者所採取的策略
- 最佳制勝策略
- 近期市集活動
- 主要公司市佔率（%），2021年
主要公司簡介
- F. Hoffmann-LA Roche Ltd.
- Siemens AG
- Thermo Fisher Scientific, Inc.
- Merck & Co, Inc.
- Agilent Technologies Inc.
- Bristol-Myers Squibb Company
- Qiagen NV
- Exact Sciences Corporation
- Novartis AG
- Bio-Rad Laboratories
- Hologic, Inc.
- bioMerieux SA
- Abbott Laboratories
- PerkinElmer, Inc.
- Illumina
Global Cancer Biomarkers Market size was valued at USD 13.24 Billion in 2022 and is poised to grow from USD 14.83 Billion in 2023 to USD 29.49 Billion by 2031, growing at a CAGR of 13.6% in the forecast period (2024-2031)
The anticipated expansion of the worldwide market for cancer biomarkers is indicative of a significant increase in the incidence of many cancer kinds, including lung, prostate, and breast cancer. The increase in cancer cases is what will fuel the market's growth during the projection period.
Furthermore, the need for efficient biomarkers is fueled by the growing importance of targeted and biological therapies in the treatment of cancer. This rising trajectory is further supported by technological improvements that improve the precision and consistency of cancer biomarkers, which in turn improves treatment monitoring and diagnostic capacities.
Global Cancer Biomarkers Market Segmental Analysis
Five segments comprise the global market for cancer biomarkers: profiling technique, cancer type, biomolecule, application, and geography. The market is divided into four segments based on profiling technology: cytogenetics-based tests, immunoassays, imaging technologies, and omic technologies. The market is divided into four segments based on biomolecules: genetic, protein, glyco-, and epigenetic biomarkers. The market is divided into categories according to the kind of cancer: breast cancer, lung cancer, colorectal cancer, prostate cancer, stomach cancer, and others. The market is divided into five segments based on application: risk assessment, prognostics, drug discovery and development, diagnostics, and others. The market is divided into the following regions: Asia-Pacific, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, Rest of Europe, North America, U.S., Canada, Mexico, Europe, Germany, UK, Italy, France, Spain, and Rest of LAMEA.
Drivers of the Global Biobanking Market
Many pharmaceutical companies are investing heavily in cutting-edge research and development projects centered on new biomarkers designed for cancer detection and therapy. A number of intriguing prospects are almost finished with their development stages and should advance significantly when they debut. These possible biomarkers have the capacity to completely transform the way that cancer is diagnosed and treated by providing increased precision and effectiveness.
Restraints in the Global Cancer Biomarkers Market
A major barrier in the cancer biomarker industry contrasts with the rising global prevalence of cancer and the growing need for diagnostic tools. the lack of comprehensive biomarker test reimbursement rules in both established and emerging countries. This deficiency limits the global demand for biomarkers by impeding the widespread adoption of these essential diagnostic tools. Another significant obstacle is the high expense of cancer detection and treatment, which is particularly common in developing nations.
Market Trends of the Global Cancer Biomarkers Market
The market for cancer biomarkers is expected to grow significantly over the next ten years due to a number of important elements coming together. Growing patient and healthcare professional knowledge of the need of early detection in treating malignancies is a key factor in this growth. This increased consciousness encourages early diagnosis in a proactive manner, resulting in prompt treatments that may lead to better treatment outcomes.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cancer Biomarkers Market by Profiling Technology
- Market Overview
- Omic Technologies
- Imaging Technologies
- Immunoassays
- and Cytogenetics-based Tests
Global Cancer Biomarkers Market by Biomolecules
- Market Overview
- Genetic Biomarkers
- Protein Biomarkers
- Epigenetics
- and Glyco-biomarkers
Global Cancer Biomarkers Market by Cancer
- Market Overview
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- and Others
Global Cancer Biomarkers Market by Application
- Market Overview
- Diagnostics
- Drug Discovery and Development
- Prognostics
- Risk Assessment
- and Others
Global Cancer Biomarkers Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- F. Hoffmann-LA Roche Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Qiagen N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio-Rad Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hologic, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- bioMerieux SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
2025-2033 年日本癌症生物標記市場報告（按分析技術、生物分子、癌症類型、應用、最終用戶和地區）
癌症生物標記市場：按生物標記類型、癌症類型、技術、應用、最終用戶 - 2025-2030 年全球預測
兒科癌症生物標記市場 - 全球產業規模、佔有率、趨勢、機會和預測，按適應症、類型、最終用途、地區和競爭細分，2019-2029F
癌症生物標記市場，按生物標記類型、癌症類型、應用、國家和地區 - 2024-2032年產業分析、市場規模、市場佔有率和預測
癌症生物標記市場規模、佔有率、成長分析，按分析技術、按癌症類型、按產品、按應用、按地區 - 行業預測，2024-2031 年
兒科癌症生物標記市場規模、佔有率、趨勢分析報告：按適應症、按生物標記、按最終用途、細分市場預測，2024-2030 年
2024-2032 年按分析技術、生物分子、癌症類型、應用、最終用戶和地區分類的癌症生物標記市場報告
癌症生物標記市場規模、佔有率、趨勢分析報告：按類型、生物分子、應用、技術、地區和細分市場預測，2024-2030
全球癌症生物標記市場：按分析技術、按癌症類型、按產品、按應用、按最終用戶、按地區 - 預測至 2029 年
癌症生物標記市場 - 按生物標記類型、癌症類型和關鍵地區：行業趨勢和全球預測